Asthma, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
Conditions
Keywords
Eczema, Dermatitis, Atopy
Brief summary
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march. Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality. This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new and individual treatment options of atopic diseases.
Detailed description
Primary Objetive: In the planned project, the main objective is to identify endogenous (e.g. immunological and molecular factors) and exogenous factors (e.g. environmental, socioeconomic and microbial factors) that influence the course and remission of AD. More specifically to identify factors that are significantly different between patients that have or do not have remission from AD. Secondary Objective: (i) To identify endogenous and exogenous factors such as immunological, molecular and microbial factors to separate subgroups of patients (endotypes) with distinct local and systemic inflammatory responses. (ii) To identify potential biomarkers predicting the individual clinical course of AD and other atopic diseases including asthma, food allergy and allergic rhinitis.
Interventions
None listed
Sponsors
University of Zurich
University of Bonn
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant.
Exclusion criteria
\- Unable to give consent or refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission of atopic dermatitis and associated allergic diseases | 5 years | Prospective observational study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endogenous and exgogenouse factors that influence and predict the course of AD. | 5 years | Prospective observational study |
| Identification of potential biomarkers predicting the course of AD | 5 years | Prospective observational study |
Countries
Switzerland
Outcome results
None listed